Skip to main
CNMD
CNMD logo

CONMED (CNMD) Stock Forecast & Price Target

CONMED (CNMD) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 29%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Conmed Corp demonstrated strong financial performance, with General Surgery sales increasing by 8.7% to $206.9 million, surpassing consensus estimates. The company's operating margin saw a significant improvement, rising 280 basis points year-over-year to 18.6%, supported by gross margin expansion and operational efficiencies. Additionally, international sales of $142.6 million grew by 5.0%, reflecting positive momentum in both Orthopedic and General Surgery segments despite ongoing supply chain challenges.

Bears say

Conmed Corp faces a negative outlook largely due to projected revenue growth slowing to 4% or less, driven by disappointing sales in key product lines and challenges with new product launches. Additionally, management's downgraded guidance for 2025 revenue and earnings per share reflects ongoing supply chain difficulties that are anticipated to negatively impact profit margins. Furthermore, the risk factors identified, including weaker revenue growth, adverse currency impacts, and reduced hospital capital spending, contribute to a precarious financial position for the company.

CONMED (CNMD) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 29% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CONMED (CNMD) Forecast

Analysts have given CONMED (CNMD) a Buy based on their latest research and market trends.

According to 14 analysts, CONMED (CNMD) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $90.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $90.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CONMED (CNMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.